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ABSTRACT 
Background: Acute kidney injury (AKI) is one of the most common complications among 
hospitalized patients and is central to the subsequent development of chronic kidney disease 
(CKD) and increased mortality. It is associated with up to five-fold increases in risk for both 
other serious complications and hospital death, and an increase in hospital cost of up to 
$28,000 per hospitalization. Timely detection of AKI and progression of AKI could avoid further 
injurious practices, and increase the chance for offering more effective preventive or therapeutic 
measures. Objective of this study is to develop and validate an electronic phenotype to identify 
patients with CKD and AKI. 
Methods: Using the University of Florida Health (UFH) Integrated Data Repository as Honest 
Broker, we created a database with electronic health records data from a retrospective study 
cohort of 84,352 adult patients hospitalized at UF Health between 1/1/2012 and 4/1/2016. This 
repository includes demographic information, comorbidities, vital signs, laboratory values, 
medications with date and timestamps, and diagnoses and procedure codes for all index 
admission encounters as well as encounters within 12 months prior to index admission and 12 
months follow-up. We developed algorithms to identify CKD and AKI based on the Kidney 
Disease: Improving Global Outcomes (KDIGO) criteria. We identified presence and stage of AKI 
by running algorithms each time a new creatinine measurement was detected. To measure 
diagnostic performance of the algorithms, the clinical adjudication of AKI and CKD on 300 
selected cases was performed.by clinician experts with access to patient medical charts. 
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 
the CKD and AKI labels produced by the algorithm were compared to clinical diagnosis. 
Results: Among 149,136 encounters, 12% had CKD by medical history, which is based on ICD-
9/10 codes. Using creatinine criteria, percent of patients with CKD identified increased to 16%. 
Among 130,081 encounters who had sufficient data for AKI phenotyping after excluding those 
with end-stage renal disease on admission, AKI during hospitalization was identified in 21% of 
encounters. The comparison of CKD phenotyping algorithm to manual chart review performed in 
300 cases yielded PPV of 0.87 (95% confidence interval (CI) 0.81-0.92), NPV of 0.99 (95% CI 
0.96-1.00), sensitivity of 0.99 (95% CI 0.96-1.00), and specificity of 0.89 (95% 0.83-0.93). The 
comparison of AKI phenotyping algorithm to manual chart review yielded PPV of 0.99 (95% CI 
0.96-1.00), NPV of 0.95 (95% CI 0.89-0.98), sensitivity 0.98 (95% CI 0.94-0.99), and specificity 
0.98 (95% CI 0.93-1.00). Instead of phenotyping algorithms, if only ICD-9/10 codes were used 
to identify AKI, comparison to manual chart review yielded PPV of 0.78 (95% CI 0.70-0.85) and 
NPV of 0.40 (95% CI 0.33-0.48), specificity of 0.71 (95% CI 0.61-0.80), and sensitivity of 0.49 
(95% CI 0.42-0.56). This sensitivity is very poor compared to the sensitivity of the algorithm, 
which also uses creatinine criteria to identify AKI.  
Conclusions: We developed phenotyping algorithms that yielded very good performance in 
identification of patients with CKD and AKI in validation cohort. This tool may be useful in 
identifying patients with kidney disease in a large population, in assessing the quality and value 
of care provided to such patients and in clinical decision support tools to help providers care for 
these patients. 
  
INTRODUCTION 
The advent of the electronic health record (EHR) with the availability of clinical data in 
digital form has transformed both clinical care and our ability to analyze that care.1 Clinical data 
is the record of clinical care provided to a patient, and chart review of clinical data remains the 
gold standard for adjudication of clinical research questions. Claims data, based on the use of 
administrative codes from billable interactions between the patient and a healthcare payer, 
provides a global view of the patient, since virtually every healthcare interaction generates a bill. 
Organizations are developing enterprise data warehouses, sometimes known as integrated data 
repositories (IDR), which aggregate data from throughout the organization including both clinical 
data from the EHR and all electronic claims data.2 Combining the broad picture of a patient seen 
using claims data, with the accurate clinical information contained within the EHR, could give 
researchers a more comprehensive view of patient care than is currently available.  
Electronic phenotype is a tool to identify and characterize clinical conditions with an 
automated query of digital clinical record.3 An electronic phenotype uses a defined set of data 
elements and logical expressions to accurately identify patients with a set of observable traits 
from the data contained within a data repository. These queries can be designed to identify 
patients with a particular condition and, ideally, to clinically stage those conditions to support 
observational and interventional research.4,5 Techniques used include a combination of data 
mining, natural language processing techniques and regression analyses.6 
Kidney diseases provide a good example of the challenges inherent in analyzing clinical 
disease data in digital clincal records, and an example of diseases to which electronic 
phenotyping could be used to good effect.7,8 A query of an EHR or IDR using administrative 
codes alone is very poor at identifying the incidence of acute kidney injury (AKI), or the 
prevalence of chronic kidney disease (CKD), within any cohort of patients.9-11 Furthermore, 
administrative codes do not reflect any of the disease severity metrics that are important in 
modern consensus definitions for AKI and CKD.8,12 Consensus definitions of both diseases, 
including clinical staging, have recently been outlined by the Kidney Disease: Improving Global 
Outcomes (KDIGO) consortium.13,14 Furthermore since both AKI and CKD can vary with time 
and interact with each other, recent epidemiologic and outcomes studies are beginning to reflect 
that reality. A recent publication by an Acute Disease Quality Initiative (ADQI) Workgroup 
proposes a nomenclature for kidney diseases across the spectrum from AKI to CKD.15 An 
episode of AKI which resolves completely within 48 hours is termed “rapid reversal” AKI and is 
believed to have minimal clinical consequences. An episode of AKI which persists beyond 48 
hours is described as “persistent” AKI, while an episode of AKI which results in renal 
dysfunction that persists beyond 7 days is described using the new term “Acute Kidney 
Disease” (AKD). Renal dysfunction persisting 90 days or longer is CKD, and CKD resulting in a 
need for renal replacement therapy (RRT) is end-stage kidney disease (ESKD). Patients with 
ESKD can undergo renal transplantation that leaves them with normal renal function or with 
less-severe CKD that does not require RRT.  
No single electronic phenotype has been developed to identify and fully characterize both AKI 
and CKD within the EHR, although a preliminary and partial CKD phenotype exists16 and 
methodologies have been developed to screen for AKI within the EHR or in electronic clinical 
registries.17-19 Here we describe the development and validation of an automated algorithm for 
comprehensive identification and characterization of kidney health in electronic health records, 
usable both retrospectively and in real time. To the best of our knowledge this is the first 
electronic phenotype that combines disparate sources of EHR data to identify stages, duration 
and renal recovery of both acute and chronic kidney disease. 
METHODS 
Data and Participants 
Using the University of Florida Health (UFH) Integrated Data Repository as Honest 
Broker, we have created two single-center longitudinal cohorts that integrated the 
comprehensive vendor-based inpatient and outpatient EHR (Epic Systems, Verona, Wisconsin, 
USA) available since 2011 with administrative, laboratory and claims data prior to 2011 and 
public datasets.20 The Algorithm Development Cohort used the Declare dataset of 51,457 
patients admitted to UFH between January 2000 and November 2010 (Figure 1). 21-24  
Figure 1. Clinical Datasets 
 
The Algorithm Verification Cohort used the PICS cohort that combines EHR and 
research data for 245 sepsis patients prospectively enrolled in longitudical cohort study at UF 
between January 2015 and July 2017.25,26 The Algorithm Validation Cohort used the AKI EPIC 
dataset of 84,350 patients admitted to UFH between January 2012 and April 2016.27 
Participants in all cohorts were adults with age  18 years at the time of admission. 
With the exception of PICS cohort, dataset represented the population receiving routine 
clinical care at the study institution. Every admission to the hospital corresponded to unique 
inpatient encounter. Each dataset included all diagnosis and procedure codes, structured and 
unstructured clinical data, demographic information, vital signs, laboratory values and 
medication data for all index inpatient encounters. For each of the patient in the dataset we 
obtained all prior administrative codes available in UFH IDR using the International 
Classification of Diseases, 9th and 10th revision, clinical modification (ICD-9-CM and ICD-10-CM, 
respectively) codes. The appropriate mapping was performed for both AKI and CKD to ensure 
that all appropriate codes were ascertained regardless of whether ICD-9 or ICD-10 codes are 
used in the EHR (Supplemental Tables 1-5). For all datasets laboratory data was available for 
within 12 months prior to index admission and 12 months follow-up. Data elements identified for 
analysis are included in the supplemental materials (Supplemental Tables 6 and 7).  
Development of the Algorithm 
We used Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice 
Guideline definitions for AKI and CKD and consensus report of the Acute Disease Quality 
Initiative (ADQI) 16 Workgroup on renal recovery as conceptual framework for the development 
of algorithm for comprehensive assessment of kidney health during inpatient hospitalization 
(eKidneyHealth).15,28,29  Using a comprehensive set of EHR data in the Algorithm Development 
Cohort, including diagnostic and procedure codes, laboratory results, clinical data and 
demographic information, we combined a rule-based methodology to develop algorithms and 
regression analysis previously proven to be replicable with strong predictive values across other 
institutions.30  
The eKidneyHealth algorithm is a complex algorithm that unifies six rule-based flow 
diagrams and regression analysis in order to identify and characterize kidney health in any 
inpatient encounter, either in real-time or in the retrospective datasets (Figure 2). 
 
Figure 2. Master Flow 
 
For every new inpatient encounter, immediatlly upon admission, the algorithm first 
determines the presence of CKD using all existing historical data prior to index admission 
(Figure 3).  
 
Figure 3. CKD Identification Flow 
 
 
 
 
 
 
The first creatinine value during index admission triggers the assessment of reference 
creatinine (Figure 4) and staging of CKD (Figure 5) while any subsequent new creatinine value 
initiates the assessment of AKI stages, renal recovery and dynamic GFR (Figure 6).   
 
 
Figure 4. Determiantion of Reference Creatinine Flow 
 
 
 
  
Figure 5. CKD Staging Flow
 
Figure 6. AKI Identification Flow 
 
 
Common to both the CKD and AKI algorithms is a single “Reference Creatinine” 
algorithm used to identify and calculate, using available data, every patient’s reference 
creatinine. It represents a patient’s creatinine in the steady state, before any new AKI occurs, 
and/or after the patient recovers from any pre-existing AKI. The flows are built from data inputs, 
conditional decision points, search and/or calculations needed, and outputs. To identify and 
stage CKD for each inpatient encounter the CKD Identification, Reference Creatinine and CKD 
Staging algorithms are run once only using data from the day of admission and historical data. 
To identify and stage any new AKI during the inpatient encounter the Reference Creatinine, AKI 
Identification and AKI Staging algorithms are run once using data from the day of admission and 
historical data, and then these three algorithms are run again every time a new creatinine 
measurement is detected.This makes sure that any AKI that develops during an inpatient 
encounter is captured, and insures that the correct reference creatinine is used in doing so.  
The algorithm was written in both Python 2.7 13 and SciPy 1.0.0 31 software.  Data 
elements were extracted from the dataset, transformed and cleaned as needed, and then 
organized into Python data structures for fast query of a patients' history. Queries were 
developed and unit-tested for each object, and then combined into Python routines to implement 
the logic of the algorithms. Each patient record in the algorithm verification PICS dataset of 245 
sepsis patients contains clinical adjudication for CKD, AKI and renal recovery status performed 
by two independent nehrologists as a part of a study protocol.26 Further development and 
editing of the code were done using this database using clinical adjusication as the gold 
standard. Code subroutines were revised in an iterative manner by running the subroutines on 
the development and then verification cohorts, with the results compared to previous clinical 
adjudication.  
Identification and staging of CKD  
The CKD Identification Flow is used to determine if the patient has any evidence of CKD 
or ESKD, and to distinguish between patients with pre-existing CKD and those with new onset 
AKI (Figure 4). The algorithm first uses all available administrative codes in patient’s medical 
record to identify patients with CKD, ESKD and any history of kidney transplantation using 
previously validated combination of ICD-9 or ICD-10 codes (Supplemental Tables 1-5). Patients 
with previous renal transplant were considered as a separate category. For subset of patients 
with available serum creatinine measurements prior to index hospitalization we used 
combination of KDIGO diagnostic criteria for CKD stage >= 3 only (risk factors for CKD and two 
creatinine measurements separated by at least three months with corresponding eGFR < 60 
ml/min/1.72m2). A subset of patients with no available previous medical history in UF EHR/IDR 
were marked as having insufficient data to determine CKD status. The algorithm also 
encounters for the episodes of AKI without renal recovery that occurred within 3 months of index 
admission. Outputs and definitions from the algorithm are listed in Supplemental Table 3. The 
CKD Staging Flow is used to calculate the patients’ eGFR G-stage using the CKD-EPI formula. 
The reference creatinine level from the Reference Creatinine Flow is used as the standardized 
serum creatinine in that formula.  
Determination of Reference Creatinine  
The Reference Creatinine Flow is used to calculate a reference serum creatinine level 
for the patient, that is subsequently used for calculation of reference eGFR, CKD staging and 
AKI identification and staging. Patients with ESKD are excluded form this algorithm. The 
algorithm is triggered to run by every creatinine measurement identified in the inpatient 
encounter. Next the algorithm determines if the creatinine measurement that has triggered this 
run of the algorithm was obtained within the first seven days of the admission (if this run of the 
algorithm is for CKD this will always be true, if this run of the algorithm is for AKI the algorithm 
determines the date of the triggering creatinine measurement). If the index creatinine 
measurement is from 8 or more days after admission the algorithm identifies either the last 
available reference creatinine or the minimum creatinine from the previous seven days as the 
reference creatinine. If the index creatinine measurement is from the first seven days of the 
admission, a list of all serum creatinine levels with time and date stamps is used to calculate the 
reference creatinine. If there were previous creatinine measurements in the interval 0-7 days 
before admission we used the minimum creatinine level during that interval as reference value 
1. If there were previous creatinine measurements in the interval 8-365 days before admission, 
we used the median creatinine level during that interval as reference value 2 (ref to NHS study 
and to Holmes paper). The reference creatinine is then the minimum of (reference value 1, 
reference value 2 and the admission creatinine) (Figure 4). 
Identification and staging of AKI and renal recovery  
The AKI Identification Flow is used determine if the patient has any evidence of current 
AKI by KDIGO criteria and to identify patients with AKI stratified by AKI maximum stages, 
duration if AKI (rapidly reversed AKI – duration < 48 hours, persistent AKI -duration > 48 hours 
and AKD – duration > 7 days) and renal recovery status (recovered vs non recovered AKI). This 
algorithm is triggered to run by every new measurements of serum creatinine in an inpatient 
encounter. We defined an episode of AKI as beginning when this algorithm identifies AKI and 
ending if there are two consecutive days without AKI identified, thus allowing us to identify a 
new episode of AKI in a patient who has recovered from a previous episode of AKI. Renal 
replacement status was determined daily, based on CPT codes and data elements from EHR 
flowsheet with order details and fluid managent for hemodialysis, peritoneal dialysis, and 
continuous renal replacement therapies (Supplemental tables 5-7). Since we have already 
excluded patients with ESKD, if the patient is undergoing RRT, identified by CPT code or by 
clinical evidence in the EHR, we assumed that the patient is currently being treated for AKI. We 
then used output from the CKD Identification algorithm, plus the date and time stamps on each 
serum creatinine measurement, to determine if the patient has new or persistent AKI by KDIGO 
criteria. Finally we determined if the patient has AKD by ADQI criteria, as well as the recovery 
trajectory since any previous episodes of AKI or AKD (Figure 6). With the AKI Staging Flow we 
determined the KDIGO AKI stage for all patients identified with AKI algorithm. If the patient was 
undergoing RRT the AKI is “Stage 3 with RRT”. If the patient was not undergoing RRT the 
current reference creatinine is used to stage the AKI (Figure 7). 
Figure 7. AKI Staging Flow
 
 
Phenotype Algorithm Validation 
The algorithms were tested and validated by comparing the perfomance of the 
phenotype in identifying patients with AKI and CKD to identification of these conditions by 
clinical experts doing review of the EHR. Performance in identifying patients with AKI was 
further evaluated by comparing identification by phenotype to identification by the AKI Code 
Algorithm. 
The ability of clinician experts, with access to all patient data within a medical chart, to 
identify patients with disease is widely accepted as the gold standard. We enlisted three 
physicans (a nephrologist, an internist and a surgeon) and a medical student trained in the 
clinical consensus definitions of AKI and CKD to independently review the validation cohort of 
patients, using their EHR, to determine if the patients had CKD at the time of admission and/or 
AKI that developed during the hospitalization. Reviewers used physician notes, nursing notes 
and laboratory results to search for clinical evidence of CKD and/or AKI.  Any differences in 
ascertainment of either CKD or AKI were arbitrated in discussion between the three reviewers 
while reviewing the EHR for the patient. We used the AKI Code Algorithm on the same 
validation cohort of patients to identify those patients who developed AKI during the 
hospitalization using administrative codes only. We then compared the ability of the full 
phenotype to identify CKD and/or AKI compared to the clinicians, and compared the ability of 
the full phenotype to identify AKI compared to the AKI Code Algortihm. Sensitivity, specificity, 
positive and negative predictive values and overall accuracy (the proportion of true classification 
including true positives plus true negatives) for ascertainment by the phenotype compared to 
ascertainment by the reference techniques were calculated with exact binomial confidence 
intervals. We also then reviewed the EHRs of the patients where there was a mismatch 
between identification by phenotype compared to identification by clinician, as an indication of 
how the phenotype failed and might be improved in the future.  
The review sample for the phenotype algorithm validation was created by randomly 
selecting inpatient encounters from the AKI Epic database based on CKD status while stratifying 
each group for reference creatinine, AKI status and renal recovery. To determine how many 
charts would be needed for review in each subgroup we assumed that, due to the selection 
criteria, the expected incidence of AKI and CKD in the validation cohort would be 50% and thus 
a p0 for power calculation would be 0.5. We specified an odds ratio of 2.0, an α of 0.05 with a 2-
sided test and a β of 0.8. The power calculation, given these criteria, indicated a necessary 
sample size of 137 for both cases and controls or a total of 274 charts. Thus in each subgroup 
the patient encounters with the 25 highest reference creatinines and the 25 lowest reference 
creatinines were chosen for review, for a total of 300 charts. The medical record numbers for 
those patient encounters were pulled and used to review each patient’s record in the Epic EHR. 
Statistical analyses were performed with SAS (version 9.4; SAS Institute, Inc, Cary, NC) and R 
software. 
Data collection and analysis 
The eKidney algorithm was ran to analyze all adult inpatient encounters in the AKI Epic 
validation database to identify and characterize all AKI and CKD episodes n those encounters. If 
a patient had more than one episode of AKI during an inpatient encounter only the highest stage 
of AKI was counted. A total of 7,646,962 inpatient encounters in the AKI Epic database, for 
patients aged 18 years or greater and admitted to the UFH between January 1, 2012 and April 
1, 2016, was used to construct the patient cohort for running and testing the final algorithm. We 
excluded all encounters that were not coded as “inpatient” or “observation” and that did not 
occur at either the Gainesville or Jacksonville UF campuses, all encounters with missing 
datetime stamps, all encounters from patients admitted in 2011 (to make sure that there was 
sufficient medical history in the EHR), all encounters with administrative codes for ESKD and all 
encounters that had no creatinine values recorded. The final cohort included 130,081 unique 
encounters from 49,520 patients (Figure 1).   
RESULTS 
Clinical Characteristics  
The basic clinical charactristics for patients without ESKD was assessed for all 3 cohorts 
(Table 1). In the full cohort of 49,522 patients, approximately 51% of the population were male, 
and the mean age was 56 years old. The percentage of AKI and CKD was both higher among 
the verification cohort. 
Table 1. Clinical characteristic for patients without ESKD for each cohort 
 
Variables  DECLARE PICS AKI EPIC 
 (n=49,522) (n=239) (n=71,127a) 
Age (years), mean (SD) 56 (17) 59 (15) 56 (19) 
Female sex, n (%) 24,307 (49) 109 (46) 36,681 (52) 
African-American ethnicity, n (%) 5,923 (12) 19 (8) 12,112 (17) 
Chronic kidney disease, n (%) 4,024 (8) 36 (15) 5,540 (8) 
Acute kidney injury, n (%) 20,225 (40) 148 (62) 13,670 (19) 
a Characteristic for first encounter of each patient is used for the non-ESKD patients with sufficient data to 
complete AKI phenotyping. 
 
 
Distribution of chronic kidney disease groups  
Among 149,136 encounters of validation cohort, 12.4% had CKD by Medical history. 
Using creatinine criteria, percent of patients with CKD identified increased to 16.9% (Table 2).  
 
Table 2. Distribution of chronic kidney disease groups 
 AKI EPIC Cohort 
n (%) 
Overall 149136 (100) 
  Insufficient Data ( No CKD with warning) 630 (0.4) 
 No CKD  123268 (82.7) 
   No CKD by Medical History Or Creatinine 
Criteria and no recent AKI episodea 
118392 (79.4) 
   No CKD by Medical History Or Creatinine 
Criteria, Recovered recent AKI on  Admission 
3483 (2.3) 
   No CKD by Medical History Or Creatinine 
Criteria, Non-recovered recent AKI (AKD) on 
admission 
1393 (0.9) 
CKD 25238 (16.9) 
 CKD by Medical History 18557 (12.4) 
   CKD by Medical History and no recent AKI 
episodea 
12365 (8.3) 
   CKD by Medical History, Recovered recent 
AKI on  Admission 
2858 (1.9) 
   CKD by Medical History, Non-recovered 
recent AKI (AKD) on Admission 
3334 (2.2) 
 CKD by Creatinine Criteria 4937 (3.3) 
   CKD by Creatinine Criteria and no recent AKI 
episodea 
3974 (2.7) 
   CKD by Creatinine Criteria, Recovered 
recent AKI on  Admission 
631 (0.4) 
   CKD by Creatinine Criteria, Non-recovered 
recent AKI (AKD) on Admission 
332 (0.2) 
 CKD after kidney transplant  1744 (1.2) 
   CKD after kidney transplant and no recent 
AKI episodea 
1038 (0.7) 
   CKD after kidney transplant, Recovered 
recent AKI on  Admission 
187 (0.1) 
   CKD after kidney transplant, Non-recovered 
recent AKI (AKD) on Admission 
519 (0.3) 
Abbreviations: AKD, acute kidney disease; CKD, chronic kidney disease; eGFR, estimated glomerular 
filtration rate. 
a Recent AKI episode defined by the presence of ICD9 or 10 codes documented in EHR in the three 
months prior to admission 
 
AKI Charachtristics 
Among 130,081 encounters who had sufficient data for AKI phenotyping after excluding 
those with end-stage renal disease on admission, AKI during hospitalization was identified in 
21% of encounters (Table 3). The maximum AKI stage was mostly stage 1 (63%), while AKI 
stage 2 and 3 were the maximum stage identified in 19% and 18% of the patients, respectively. 
Twelve percent of patients developed more than one episode of AKI. 
Table 3. Renal characteristics among encounters with no end-stage renal disease on admission 
 
 AKI EPIC Cohort 
(N=130,081) 
No AKI during hospitalization, n (%) 103089 (79.2) 
AKI during hospitalization, n (%) 26992 (20.8) 
Maximum AKI Stage, n (%)   
   Stage 1  16949 (62.8) 
   Stage 2 5236 (19.3) 
   Stage 3 (with or without RRT) 4807 (17.8) 
RRT, n (%) 1306 (4.2) 
Number of days on RRT, median (25th, 50th, 75th) 10 (5, 20) 
Recurrent AKI, n (%) 3310 (12.3) 
AKI duration, days, median (25th, 50th, 75th) 2 (1, 5) 
AKI trajectories  
   Rapidly reversed AKI 10163 (37.7) 
   Persistent AKI 16829 (62.3) 
Abbreviations: AKI, acute kidney injury; RRT, renal replacement therapy 
Recurrent AKI is defined as number of AKI episodes more than one.  
 
           
Comparison of phenotyping algorithms performance to manual chart review. 
 
CKD Stages among all encounters with 
CKD  
 
   G1 (eGFR ≥ 90 ml/min/1.73m2) 4424 (17.5) 
   G2 (90>eGFR ≥ 60 ml/min/1.73m2) 8098 (32.1) 
   G3a (60>eGFR ≥ 45 ml/min/1.73m2) 5668 (22.5) 
   G3b (45>eGFR ≥ 30 ml/min/1.73m2) 4314 (17.1) 
   G4 (30>eGFR ≥ 15 ml/min/1.73m2) 2071 (8.2) 
   G5 ( eGFR < 15 ml/min/1.73m2) 410 (1.6) 
   No staging can be done 253 (1) 
CKD and AKI phenotyping algorithms performed well with diagnostic performance 
measures above 0.90. (Tables 4, 5). 
Table 4. Comparison of chronic kidney disease phenotyping algorithm performance to manual 
chart review. 
  Manual chart review 
Phenotyping Algorithm Case Control Total 
Case 131 19a 150 
Control 1b 149 150 
Total 132 168 300 
PPV (95% CI) 0.87 (0.81, 0.92) 
NPV (95% CI) 0.99 (0.96, 1.00) 
Sensitivity (95% CI) 0.99 (0.96, 1.00) 
Specificity (95% CI) 0.89 (0.83, 0.93) 
Accuracy (95% CI) 0.93 (0.90, 0.96) 
Abbreviations. CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value;   
ICD, International Classification of Diseases.  
Reasons for mismatches between phenotyping algorithm and manual chart review includes: 
aAssignment of wrong ICD code for patient who had AKI (n=4), Assignment of wrong ICD code (n=2), 
Assignment of wrong ICD code for nephrotic syndrome (n=4), and Non-specific CKD code for patient who 
had AKI (n=9) 
bAlgorithm missed CKD by creatinine criteria (n=1)  
 
Table 5. Comparison of Acute kidney injury phenotyping algorithm performance and ICD-9/10 
codes to manual chart review. 
  Manual chart review 
Phenotyping Algorithm Case Control Total 
Case 198 2a 200 
Control 5b 95 100 
Total 203 97 300 
PPV (95% CI) 0.99 (0.96, 1.00) 
NPV (95% CI) 0.95 (0.89, 0.98) 
Sensitivity (95% CI) 0.98 (0.94, 0.99) 
Specificity (95% CI) 0.98 (0.93, 1.00) 
Accuracy (95% CI) 0.98 (0.95, 0.99) 
Abbreviations. CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value;   
ICD, International Classification of Diseases.  
Reasons for mismatches between phenotyping algorithm and manual chart review includes:  
aReference creatinine wrong based on erroneous laboratory measurement (n=2)  
bWrong reference creatinine due to insufficient creatinine history for CKD patient (n=2) and Wrong 
reference creatinine due to wrong CKD code assignment (n=3) 
 
DISCUSSION 
Acute kidney injury and chronic kidney disease are common, interrelated, and cause 
significant morbidity and mortality for patients. 32,33 Outcomes are the worst for patients with 
severe AKI and/or CKD, but they degrade even for patients with mild and moderate disease.34,35 
The ability to automatically identify and stage patients with AKI and CKD within a data repository 
of clinical data would facilitate clinical and health services research and, if done in real time, 
could greatly facilitate clinical decision support.22,36 In this work we developed and validated a 
novel methodology to identify adult patients with kidney disease using both clinical and claims 
data in an integrated data repository. We applied the technique of electronic phenotyping in a 
large retrospective cohort of hospitalized patients to translate a clinician’s approach to 
assessing AKI and CKD into a set of computer algorithms. We developed a phenotype for adult 
kidney health that allowed us to identify patients with both AKI and CKI, to clinically stage those 
diseases and to assess any recovery from AKI that occurs during the inpatient hospital stay. 
The overall algorithm is constructed from three algorithms to identify CKD plus three algorithms 
to identify AKI, with both using a common “Reference Creatinine” algorithm used to identify 
every patient’s baseline creatinine and which is updated every time a new serum creatinine 
value is identified. The outputs from the overall algorithm include CKD by medical history and/or 
creatinine criteria including ESKD, AKD and recovered AKI, KDIGO G-stage of any CKD, new 
and persistent AKI, recovery from AKI and from AKD, and KDIGO stage of any AKI. 
Kidney disease is commonly divided clinically into acute kidney injury (AKI) and chronic 
kidney disease (CKD), although both diseases exist on a spectrum of overall kidney health.37 
While AKI is often seen as an acute complication of surgery, as drug toxicity or as a result of 
trauma or sepsis, CKD is a chronic illness most commonly associated with diabetes and/or 
hypertension. Despite this clinical and logical separation, there is significant overlap between 
the entities.38 An episode of AKI can become CKD if there is no recovery after the initial insult. 
Patients with CKD are at higher risk for developing AKI compared to patients without CKD, while 
an episode of AKI puts a patient at higher risk for developing CKD even if the episode of AKI 
resolves completely. Both AKI and CKD increase a patient’s risk for other diseases, especially 
cardiovascular diseases. 23,39 
Patients with clinical disease can be identified within a database of clinical information, 
as is contained within a database of EHRs, or they can be identified within a database billing or 
claims data made up of administrative codes as in the National Inpatient Sample.40,41 Research 
using clinical data once required laborious and time-consuming manual review of paper charts, 
but can now be done quickly through automated review of EHRs. Clinical data contains the full 
richness of a patient’s medical history, but is limited to information from only one provider, one 
hospital, or at most one delivery system, and care provided outside of those constraints is not 
available for analysis.42 Claims data can provide a global picture of care provided to any patient, 
but it cannot provide a complete clinical picture as there is often minimal or no information on 
disease severity and coding accuracy can be problematic.43,44 While the clinical information 
contained within billing data is becoming more dense and granular with every revision of the 
coding systems, using billing data in the analysis of clinical disease requires much more clinical 
information than is currently available in claims data. An automated approach to identifying and 
characterizing disease that combines the global picture seen in administrative codes, with the 
clinical detail provided in EHR data, could provide accurate and reliable inferences about the 
presence and severity of clinical illness.45,46 
Originally developed by genomics researchers, to query EHRs to accurately capture all 
patients with rare genetic diseases, the electronic phenotype is finding wider use in both clinical 
and health services research applications.47 The goal in electronic phenotyping is to accurately 
identify patients with a specific observable trait from the large volumes of imperfect and/or 
incomplete practice-based data contained within the EHR 3 The Electronic Medical Records and 
Genomics (eMERGE) Network, an international consortium of genetics researchers, publishes 
best practices in developing and using phenotyping algorithms and helped establish an online 
repository, the Phenotype Knowledgebase (https://phekb.org), where phenotypes can be 
published and then validated at other participating institutions.30,48 Phenotypes that include 
clinical data such as medication records, clinical progress notes, and laboratory and radiology 
data notes along with administrative codes have demonstrated much improved disease 
identification as measured by positive and negative predictive values compared to identification 
using administrative data alone.42,49 
We evaluated the ability of the kidney health phenotype to identify patients with kidney 
disease against the gold standard of clinical chart review and against the process of identifying 
patients solely by using administrative data. The performance of the phenotype in identifying 
AKI and CKD exceeds existing tools and greatly improves upon the ability to capture AKI using 
administrative codes alone.50-52 Importantly the phenotype performs well across the spectrum of 
disease severity including minor stages of AKI. Recent studies have demonstrated the ability of 
identification tools that emphasize severe kidney injury, such as the Major Adverse Kidney 
Events by 30 days (MAKE30) composite of death, new renal replacement therapy, or persistent 
renal dysfunction to retrospectively identify AKI in the EHR with high sensitivity and specificity.53 
However methods to capture mild and moderate AKI in the EHR are lacking.7 Mild to moderate 
AKI is much more common than severe AKI, and has become much more appreciated with the 
introduction of consensus definitions for AKI.54 Recent work using modern consensus definitions 
of AKI have shown that when properly defined AKI is one of the most prevalent complications 
seen in hospitalized patients, is associated with other adverse events, results in an increase in 
resource utilization and increases in both short- and long-term mortality.32,34,55,56 The ability to 
more accurately identify AKI and CKD in retrospective analysis of large medical databases will 
improve the ability to measure the costs of care, the costs of complications of care and the 
assessment of provider clinical performance.57,58 Perhaps even more importantly, the ability to 
accurately identify AKI in real-time or close to real-time analysis of data within the EHR may 
lead to earlier and better care for the patients that have just been identified with new or 
worsening AKI.50-52 
Limitations 
This work, despite the performance of the phenotype, has some significant limitations. 
One important limitation is related to how the the electronic phenotype was developed.  To the 
extent that the phenotype relies on administrative codes for AKI and CKD it is dependant upon 
accurate and precise coding of diseases in the EHR, a reality that is rarely if ever achieved. 
Since identification of both AKI and CKD are dependant upon by changes in serum creatinine 
and in a determination of baseline creatinine, the phenotype misses other important clinical 
signs of kidney injury and illness. Oliguria, or decreased urine output, is an important predictor 
and early sign of kidney injury and is not captured in this phenotype. Changes is urine and 
serum biomarkers, an important and evolving technology to identify AKI and CKD, is not 
captured in the phenotype. Finally the phenotype as built is largely diagnosis agnostic. While it 
does capture administrative codes for a wide variety of kidney diseases, at the end it just 
identifies a patient with AKI and/or CKD with KDIGO staging, but it does not capture specific 
etiologies of either condition and thus misses important clinical information related to etiology. 
The performance of the phenotype needs to be further evaluated, to determine its ability to 
accurately measure the temporal aspects of AKI and CKD and renal recovery if any, and to 
determine its performance in the outpatient setting. 
Conclusion 
We have described the development and validation of an electronic phenotype for 
kidney health in hospitalized adult patients. This tool could improve studies into the 
epidemiology of AKI and CKD, could improve the assessment of the costs of these conditions 
and the quality of care, and could hasten the development of effective and early alerts for AKI. 
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SUPPLEMENTAL TABLES 
Table S1. Administrative codes used for end stage kidney disease  
 
ICD Code Explanation 
ICD-9-CM Diagnosis  
   585.6 End stage kidney disease 
   V45.1 
Renal dialysis status  
Excludes:admission for dialysis treatment or session (V56.0) 
   V45.11 
Renal dialysis status 
Hemodialysis status 
Patient requiring intermittent renal dialysis 
Peritoneal dialysis status 
Presence of arterial-venous shunt (for dialysis) 
   V45.12 Noncompliance with renal dialysis 
ICD-10-CM Diagnosis  
   N18.6 End stage kidney disease 
   Z91.15 Patient's noncompliance with renal dialysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Administrative codes used for chronic kidney disease  
 
ICD Code Explanation 
ICD-9-CM 
Diagnosis 
 
   403.00 Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or 
unspecified 
   403.01 Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage kidney 
disease 
   403.10 Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or 
unspecified 
   403.11 Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage kidney disease 
   403.90 Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or 
unspecified 
   403.91 Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage kidney 
disease 
   404.00 Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease 
stage I through stage IV, or unspecified 
   404.01 Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease 
stage I through stage IV, or unspecified 
   404.02 Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease 
stage V or end stage kidney disease 
   404.03 Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease 
stage V or end stage kidney disease 
   404.10 Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease 
stage I through stage IV, or unspecified 
   404.11 Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage 
I through stage IV, or unspecified 
   404.12 Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease 
stage V or end stage kidney disease 
   404.13 Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V 
or end stage kidney disease 
   404.90 Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney 
disease stage I through stage IV, or unspecified 
   404.91 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease 
stage I through stage IV, or unspecified 
   404.92 Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney 
disease stage V or end stage kidney disease 
   404.93 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage 
V or end stage kidney disease 
   581 Nephrotic syndrome 
   581.0 Nephrotic syndrome with lesion of proliferative glomerulonephritis 
   581.1 Nephrotic syndrome with lesion of membranous glomerulonephritis 
   581.2 Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis 
   581.3 Nephrotic syndrome with lesion of minimal change glomerulonephritis 
   581.8 Nephrotic syndrome with other specified pathological lesion in kidney 
   581.81 Nephrotic syndrome in diseases classified elsewhere 
   581.89 Nephrotic syndrome with other specified pathological lesion in kidney 
   581.9 Nephrotic syndrome with unspecified pathological lesion in kidney 
   582 Chronic glomerulonephritis 
   582.0 Chronic glomerulonephritis with lesion of proliferative glomerulonephritis 
   582.1 Chronic glomerulonephritis with lesion of membranous glomerulonephritis 
   582.2 Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis 
   582.4 Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis 
   582.8 Chronic glomerulonephritis with other specified pathological lesion in kidney 
   582.81 Chronic glomerulonephritis in diseases classified elsewhere 
   582.89 Chronic glomerulonephritis with other specified pathological lesion in kidney 
   582.9 Chronic glomerulonephritis with unspecified pathological lesion in kidney 
   583 Nephritis and nephropathy, not specified as acute or chronic 
   583.0 Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis 
   583.1 Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis 
   583.2 Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative 
glomerulonephritis 
   583.4 Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive 
glomerulonephritis 
   583.6 Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis 
   583.7 Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis 
   583.8 Nephritis and nephropathy not specified as acute or chronic with other specified pathological lesion in kidney  
   583.81 Nephritis and nephropathy, not specified as acute or chronic, in diseases classified elsewhere 
   583.89 Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney 
   583.9 Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney 
   585 Chronic kidney disease (ckd) 
   585.1 Chronic kidney disease, Stage I 
   585.2 Chronic kidney disease, Stage II (mild) 
   585.3 Chronic kidney disease, Stage III (moderate) 
   585.4 Chronic kidney disease, Stage IV (severe) 
   585.9 Chronic kidney disease, unspecified 
   586 Renal failure, unspecified 
   250.40 Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled 
   250.41 Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled 
   250.42 Diabetes with renal manifestations, type II or unspecified type, uncontrolled 
   250.43 Diabetes with renal manifestations, type I [juvenile type], uncontrolled 
   588.8 Other specified disorders resulting from impaired renal function  
   588.81 Secondary hyperparathyroidism (of renal origin) 
   588.89 Other specified disorders resulting from impaired renal function 
   588.9 Unspecified disorder resulting from impaired renal function 
   753.13 Polycystic kidney, autosomal dominant 
ICD-10-CM 
Diagnosis  
   I12.0  Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage kidney disease 
   I12.9  Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified 
chronic kidney disease 
   I13.0  Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney 
disease, or unspecified chronic kidney disease 
   I13.1  Hypertensive heart and chronic kidney disease without heart failure 
   I13.10 Hypertensive heart and chronic kidney disease without heart failure with stage 1 through stage 4 chronic kidney 
disease, or unspecified chronic kidney disease 
   I13.11  Hypertensive heart and chronic kidney disease without heart failure with stage 5 chronic kidney disease, or end 
stage kidney disease 
   I13.2  Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or 
end stage kidney disease 
   N01  Rapidly progressive nephritic syndrome 
   N01.0 Rapidly progressive nephritic syndrome with minor glomerular abnormality 
   N01.1 Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions 
   N01.2  Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis 
   N01.3 Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis 
   N01.4  Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis 
   N01.5  Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis 
   N01.6  Rapidly progressive nephritic syndrome with dense deposit disease 
   N01.7  Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis 
   N01.8  Rapidly progressive nephritic syndrome with other morphologic changes 
   N01.9  Rapidly progressive nephritic syndrome with unspecified morphologic changes 
   N02.0  Recurrent and persistent hematuria with minor glomerular abnormality 
   N02.1  Recurrent and persistent hematuria with focal and segmental glomerular lesions 
   N02.2  Recurrent and persistent hematuria with diffuse membranous glomerulonephritis 
   N02.3  Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis 
   N02.4  Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis 
   N02.5  Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis 
   N02.6  Recurrent and persistent hematuria with dense deposit disease 
   N02.7  Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis 
   N02.8  Recurrent and persistent hematuria with other morphologic changes 
   N02.9  Recurrent and persistent hematuria with unspecified morphologic changes 
   N03  Chronic nephritic syndrome 
   N03.0  Chronic nephritic syndrome with minor glomerular abnormality 
   N03.1  Chronic nephritic syndrome with focal and segmental glomerular lesions 
   N03.2  Chronic nephritic syndrome with diffuse membranous glomerulonephritis 
   N03.3  Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis 
   N03.4  Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis 
   N03.5  Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis 
   N03.6  Chronic nephritic syndrome with dense deposit disease 
   N03.7  Chronic nephritic syndrome with diffuse crescentic glomerulonephritis 
   N03.8  Chronic nephritic syndrome with other morphologic changes 
   N03.9  Chronic nephritic syndrome with unspecified morphologic changes 
   N04  Nephrotic syndrome 
   N04.0 Nephrotic syndrome with minor glomerular abnormality 
   N04.1  Nephrotic syndrome with focal and segmental glomerular lesions 
   N04.2  Nephrotic syndrome with diffuse membranous glomerulonephritis 
   N04.3  Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis 
   N04.4  Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis 
   N04.5  Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis 
   N04.6  Nephrotic syndrome with dense deposit disease 
   N04.7  Nephrotic syndrome with diffuse crescentic glomerulonephritis 
   N04.8  Nephrotic syndrome with other morphologic changes 
   N04.9  Nephrotic syndrome with unspecified morphologic changes 
   N05  Unspecified nephritic syndrome 
   N05.0  Unspecified nephritic syndrome with minor glomerular abnormality 
   N05.1  Unspecified nephritic syndrome with focal and segmental glomerular lesions 
   N05.2  Unspecified nephritic syndrome with diffuse membranous glomerulonephritis 
   N05.3  Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis 
   N05.4  Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis 
   N05.5  Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis 
   N05.6  Unspecified nephritic syndrome with dense deposit disease 
   N05.7  Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis 
   N05.8  Unspecified nephritic syndrome with other morphologic changes 
   N05.9  Unspecified nephritic syndrome with unspecified morphologic changes 
   N06  Isolated proteinuria with specified morphological lesion 
   N06.0  Isolated proteinuria with minor glomerular abnormality 
   N06.1  Isolated proteinuria with focal and segmental glomerular lesions 
   N06.2  Isolated proteinuria with diffuse membranous glomerulonephritis 
   N06.3  Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis 
   N06.4  Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis 
   N06.5  Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis 
   N06.6  Isolated proteinuria with dense deposit disease 
   N06.7  Isolated proteinuria with diffuse crescentic glomerulonephritis 
   N06.8  Isolated proteinuria with other morphologic lesion 
   N06.9  Isolated proteinuria with unspecified morphologic lesion 
   N07  Hereditary nephropathy, not elsewhere classified 
   N07.0  Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality 
   N07.1  Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions 
   N07.2  Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis 
   N07.3  Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis 
   N07.4  Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis 
   N07.5  Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis 
   N07.6  Hereditary nephropathy, not elsewhere classified with dense deposit disease 
   N07.7  Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis 
   N07.8  Hereditary nephropathy, not elsewhere classified with other morphologic lesions 
   N07.9  Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions 
   E08.2  Diabetes mellitus due to underlying condition with kidney complications 
   E08.21 Diabetes mellitus due to underlying condition with diabetic nephropathy 
   E08.22  Diabetes mellitus due to underlying condition with diabetic chronic kidney disease 
   E08.29 Diabetes mellitus due to underlying condition with other diabetic kidney complication 
   E09.2  Drug or chemical induced diabetes mellitus with kidney complications 
   E09.21  Drug or chemical induced diabetes mellitus with diabetic nephropathy 
   E09.22  Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease 
   E09.29  Drug or chemical induced diabetes mellitus with other diabetic kidney complication 
   E10.2  Type 1 diabetes mellitus with kidney complications 
   E10.21 Type 1 diabetes mellitus with diabetic nephropathy 
   E10.22  Type 1 diabetes mellitus with diabetic chronic kidney disease 
   E10.29  Type 1 diabetes mellitus with other diabetic kidney complication 
   E11.2  Type 2 diabetes mellitus with kidney complications 
   E11.21  Type 2 diabetes mellitus with diabetic nephropathy 
   E11.22  Type 2 diabetes mellitus with diabetic chronic kidney disease 
   E11.29  Type 2 diabetes mellitus with other diabetic kidney complication 
   E13.2 Other specified diabetes mellitus with kidney complications 
   E13.21  Other specified diabetes mellitus with diabetic nephropathy 
   E13.22  Other specified diabetes mellitus with diabetic chronic kidney disease 
   E13.29  Other specified diabetes mellitus with other diabetic kidney complication 
   N25  Disorders resulting from impaired renal tubular function 
   N25.8  Other disorders resulting from impaired renal tubular function 
   N25.81  Secondary hyperparathyroidism of renal origin 
   N25.89  Other disorders resulting from impaired renal tubular function 
   N25.9  Disorder resulting from impaired renal tubular function, unspecified 
   Q61  Cystic kidney disease 
   Q61.2  Polycystic kidney, adult type 
   Q61.3  Polycystic kidney, unspecified 
   Q61.4  Renal dysplasia 
   Q61.5  Medullary cystic kidney 
   Q61.8  Other cystic kidney diseases 
   Q61.9 Cystic kidney disease, unspecified 
   N18.1  Chronic kidney disease, stage 1 
   N18.2  Chronic kidney disease, stage 2 (mild) 
   N18.3  Chronic kidney disease, stage 3 (moderate) 
   N18.4  Chronic kidney disease, stage 4 (severe) 
   N18.5  Chronic kidney disease, stage 5 
   N18.9 Chronic kidney disease, unspecified 
   N28  Other disorders of kidney and ureter, not elsewhere classified 
   N28.0  Ischemia and infarction of kidney 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Administrative codes for kidney transplant  
 
ICD Code Explanation 
ICD-9-CM Diagnosis  
   V42.0 Kidney replaced by transplant 
   996.81 Complications of transplanted kidney 
ICD-9-CM Procedure  
   55.6 Transplant of Kidney 
   55.61 Renal autotransplantation 
   55.69 Other kidney transplantation 
ICD-10-CM Diagnosis  
   Z94.0 Kidney transplant status 
   T86.10 Unspecified complication of kidney transplant 
   T86.11   Kidney transplant rejection 
   T86.12  Kidney transplant failure 
   T86.13 Kidney transplant infection 
   T86.19 Other complication of kidney transplant 
ICD-10-PCS Procedure  
   0TS00ZZ  Reposition Right Kidney, Open Approach 
   0TS10ZZ Reposition Left Kidney, Open Approach 
   0TY00Z0  Transplantation of Right Kidney, Allogeneic, Open Approach 
   0TY00Z1  Transplantation of Right Kidney, Syngeneic, Open Approach 
   0TY10Z0  Transplantation of Left Kidney, Allogeneic, Open Approach 
   0TY10Z1 Transplantation of Left Kidney, Syngeneic, Open Approach 
CPT   
   50360 Renal allotransplantation, implantation of graft; without recipient nephrectomy 
   50365 Renal allotransplantation, implantation of graft; with recipient nephrectomy 
   50380 Renal autotransplantation, reimplantation of kidney 
 
Abbreviations. ICD, The International Classification of Diseases; ICD-9-CM, The International 
Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM, International Classification of 
Diseases, Tenth Revision, Clinical Modification; ICD-10-PCS, The International Classification of 
Diseases, 10th Revision, Procedure Coding System; CPT, Current Procedural Terminology 
 
 
 
Table S4. ICD codes used for history of acute kidney injury 
 
ICD Code Explanation 
ICD-9-CM 
Diagnosis 
 
   584 Acute kidney failure  
   584.5 Acute kidney failure with lesion of tubular necrosis convert  
   584.6 Acute kidney failure with lesion of renal cortical necrosis convert  
   584.7 Acute kidney failure with lesion of renal medullary [papillary] necrosis  
   584.8 Acute kidney failure with other specified pathological lesion in kidney  
   584.9 Acute kidney failure, unspecified 
   593.9 
Unspecified disorder of kidney and ureter (includes renal disease (chronic) not 
otherwise specified) 
   997.5 Urinary complications, not elsewhere classified 
ICD-10-CM 
Diagnosis  
   N17  Acute kidney failure 
   N17.0 Acute kidney failure with tubular necrosis 
   N17.1  Acute kidney failure with acute cortical necrosis 
   N17.2  Acute kidney failure with medullary necrosis 
   N17.8 Other acute kidney failure 
   N17.9 Acute kidney failure, unspecified 
   N28.9  Disorder of kidney and ureter, unspecified 
 
Abbreviations. ICD, The International Classification of Diseases; ICD-9-CM, The International 
Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM, International Classification of 
Diseases, Tenth Revision, Clinical Modification 
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Table S5. Administrative codes used for renal-replacement therapy  
ICD Code Explanation 
ICD-9-CM Diagnosis  
   V45.12 Noncompliance with renal dialysis 
   V56.0 Encounter for extracorporeal dialysis 
   V56.8 Encounter for other dialysis 
   V56.1 Fitting and adjustment of extracorporeal dialysis catheter 
   V56.2 Fitting and adjustment of peritoneal dialysis catheter 
   V56.32 Encounter for adequacy testing for peritoneal dialysis 
   V45.1 Renal dialysis status 
   V45.11 Renal dialysis status 
   996.56 Mechanical complication due to peritoneal dialysis catheter 
   996.68 Infection and inflammatory reaction due to peritoneal dialysis catheter 
   792.5 Cloudy (hemodialysis) (peritoneal) dialysis effluent 
ICD-9-CM Procedure  
   39.95 Hemodialysis 
   54.98 Peritoneal dialysis 
ICD-10-CM Diagnosis  
   Z91.15 Patient's noncompliance with renal dialysis 
   Z49.31 Encounter for adequacy testing for hemodialysis 
   Z49.32 Encounter for adequacy testing for peritoneal dialysis 
   Z49.01 Encounter for fitting and adjustment of extracorporeal dialysis catheter 
   Z49.02 Encounter for fitting and adjustment of peritoneal dialysis catheter 
   Z49.32 Encounter for adequacy testing for peritoneal dialysis 
   T85.71XA 
Infection and inflammatory reaction due to peritoneal dialysis catheter, initial 
encounter 
   T85.611A Breakdown (mechanical) of intraperitoneal dialysis catheter, initial encounter 
   T85.621A Displacement of intraperitoneal dialysis catheter, initial encounter 
   R88.0 Cloudy (hemodialysis) (peritoneal) dialysis effluent 
   T85.631A Leakage of intraperitoneal dialysis catheter, initial encounter 
   T85.71XA Infection and inflammatory reaction due to peritoneal dialysis catheter 
   T85.71XS Infection and inflammatory reaction due to peritoneal dialysis catheter, sequela 
   Z99.2 Dependence on renal dialysis 
   T85.71XD 
Infection and inflammatory reaction due to peritoneal dialysis catheter, 
subsequent encounter 
   Z99.2 Dependence on renal dialysis 
ICD-10-PCS Procedure  
   5A1D00Z  Performance of Urinary Filtration, Single 
   5A1D60Z Performance of Urinary Filtration, Multiple 
   3E1M39Z Irrigation of Peritoneal Cavity using Dialysate, Percutaneous Approach 
CPT  
   90935 
Hemodialysis procedure with single evaluation by a physician or other qualified 
health care professional 
   90937 
Hemodialysis procedure requiring repeated evaluation(s) with or without 
substantial revision of dialysis prescription 
   90945 
Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, 
hemofiltration, or other continuous renal replacement therapies), with single 
evaluation by a physician or other qualified health care professional 
   90947 
Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, 
hemofiltration, or other continuous renal replacement therapies) requiring 
repeated evaluations by a physician or other qualified health care professional, 
with or without substantial revision of dialysis prescription 
   90999 Unlisted dialysis procedure, inpatient or outpatient 
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Abbreviations. ICD, The International Classification of Diseases; ICD-9-CM, The International 
Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM, International Classification of 
Diseases, Tenth Revision, Clinical Modification; ICD-10-PCS, The International Classification of 
Diseases, 10th Revision, Procedure Coding System; CPT, Current Procedural Terminology 
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Table S6. Data elements that are used to run CKD phenotyping algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Features Description  Format  
patient_deiden_id Deidentified Patient ID Strings 
encounter_deiden_id Deidentified Encounter ID  Strings 
admit_datetime Hospital Admission Date and Time Date and Time 
dischg_datetime Discharge Date and Time Date and Time 
birth_date Birth Date Date and Time 
sex Sex Strings 
race Race Strings 
ethnicity Ethnicity Strings 
patient_type Patient Type Strings 
start_date Diagnosis Start Date Date 
diag_code Diagnosis Code Strings 
diag_icd_type Diagnosis Code Type Strings 
proc_date Procedure Date Date 
proc_code_type Procedure Code Type Strings 
proc_code Procedure Code Strings 
lab_result Lab Result Float 
lab_unit Lab Unit Strings 
inferred_specimen_datetime Inferred Specimen Taken Date and Time Date and Time 
stamped_and_inferred_loinc_code Stamped and Inferred LOINC Code Strings 
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Table S7. Data elements that are used to run AKI phenotyping algorithm 
 
a Data elements that are used for determining dialysis status in addition to CPT codes. Patient is 
considered to be on dialysis when the type of vital signs measured  is “Treatment Type” and the 
measured value of the vital is CVVH or CVVHD or CVVHDF or if there is  non-zero hemodialysis or 
peritoneal dialysis intake or output. 
Abbreviations. CVVH, Continuous Veno-Venous Hemofiltration; CVVHD, Continuous Venovenous 
Hemodialysis; CVVHDF, Continuous Venovenous Hemodiafiltration 
 
Features Description  Format  
patient_deiden_id Deidentified Patient ID Strings 
encounter_deiden_id Deidentified Encounter ID  Strings 
Code CPT code Strings 
Proc Date Date for CPT code Date 
vital_sign_measure_namea The type of vital signs measured Strings 
meas_valuea The measured value of the vital Strings 
recorded_timea The date and time of measurement Date and Time 
hemodialysis_intakea Intake value for hemodialysis Float 
hemodialysis_outputa Output value for hemodialysis Float 
peritoneal_dialysis_intakea Intake value for Peritoneal Dialysis Float 
peritoneal_dialysis_outputa Output value for Peritoneal Dialysis Float 
observation_datetimea Date and time for measurement for dialysis 
intake and output 
Date and Time 
lab_result Lab Result Float 
lab_unit Lab Unit Strings 
inferred_specimen_datetime Inferred Specimen Taken Date and Time Date and Time 
stamped_and_inferred_loinc_code Stamped and Inferred LOINC Code Strings 
